Caricamento...
Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation with steroids, with increasing use of rituxim...
Salvato in:
| Pubblicato in: | Blood |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Society of Hematology
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7918179/ https://ncbi.nlm.nih.gov/pubmed/33280030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006052 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|